Overview

Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.

Status:
COMPLETED
Trial end date:
2024-05-17
Target enrollment:
Participant gender:
Summary
This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administration of CKD-501, D745, and D150 for healthy subjects in fed state
Phase:
PHASE1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical